Bausch & Lomb (BLCO) Gross Margin (2021 - 2026)
Bausch & Lomb's (BLCO) quarterly Gross Margin came in at 62.2% in Q2 2026, up 312.0% on a YoY basis from 15.1% in Q2 2025, and up 1.54% quarter-over-quarter from 61.25% in Q1 2026.
Powered by 
Analysis
Bausch & Lomb (BLCO) Gross Margin (2021 - 2026) Analysis & Trends
Bausch & Lomb (BLCO) has reported Gross Margin for 6 consecutive years, with 62.2% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin rose 312.0% year-over-year to 62.2%; the trailing twelve-month figure through Jun 2026 stood at 61.5% (up 171.0% YoY), and the FY2025 full-year result was 59.91%, down 110.0% from the prior year.
- Gross Margin advanced to 62.2% in Q2 2026 per BLCO's latest filing, from 61.25% in the prior quarter.
- Across five years, Gross Margin topped out at 62.2% in Q2 2026 and bottomed at 57.7% in Q1 2025.
- Historically, Gross Margin has averaged 60.46% across 5 years, with a median of 60.71% in 2022.
- The sharpest annual moves came in 2025 and 2026: Gross Margin sank 381 bps in 2025, then soared 356 bps in 2026.
- Over 5 years, Gross Margin stood at 58.03% in 2022, then grew by 5 bps to 60.7% in 2023, then increased by 1 bps to 61.02% in 2024, then rose by 2 bps to 62.14% in 2025, then climbed by 0 bps to 62.2% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 62.2%, 61.25%, and 62.14% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 57.71% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 67.78% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 64.99% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 68.27% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 70.71% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 77.46% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 60.21% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 63.44% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 45.84% |
| 10 | Bausch & Lomb | 6.28 Bn | 5.90 Bn | 867.00 Mn | 62.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.20% |
| Mar 31, 2026 | 61.25% |
| Dec 31, 2025 | 62.14% |
| Sep 30, 2025 | 60.27% |
| Jun 30, 2025 | 59.08% |
| Mar 31, 2025 | 57.70% |
| Dec 31, 2024 | 61.02% |
| Sep 30, 2024 | 61.20% |
| Jun 30, 2024 | 60.36% |
| Mar 31, 2024 | 61.51% |
| Dec 31, 2023 | 60.70% |
| Sep 30, 2023 | 61.17% |
| Jun 30, 2023 | 59.71% |
| Mar 31, 2023 | 60.15% |
| Dec 31, 2022 | 58.03% |
| Sep 30, 2022 | 60.72% |
| Jun 30, 2022 | 59.94% |
| Mar 31, 2022 | 61.08% |
| Dec 31, 2021 | 59.84% |
| Sep 30, 2021 | 61.96% |